New Risk • Mar 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$2.4m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Earnings have declined by 5.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (NZ$11.5m market cap, or US$6.90m). Minor Risk Revenue is less than US$5m (NZ$2.4m revenue, or US$1.4m). Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Non-Executive Director Tony Barclay was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Jan 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (NZ$9.47m market cap, or US$5.46m). Minor Risk Revenue is less than US$5m (NZ$1.8m revenue, or US$1.1m). Reported Earnings • Oct 04
Full year 2025 earnings released: NZ$0.018 loss per share (vs NZ$0.087 loss in FY 2024) Full year 2025 results: NZ$0.018 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.83m (up 477% from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Ankündigung • Sep 12
Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million. Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,333,333
Price\Range: NZD 0.03
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,666,666
Price\Range: NZD 0.03
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,733,333
Price\Range: NZD 0.03
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,333,333
Price\Range: NZD 0.03
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,666,667
Price\Range: NZD 0.03
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 400,000
Price\Range: NZD 0.03
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 666,667
Price\Range: NZD 0.03
Transaction Features: Subsequent Direct Listing Reported Earnings • Sep 02
Full year 2025 earnings released: NZ$0.02 loss per share (vs NZ$0.087 loss in FY 2024) Full year 2025 results: NZ$0.02 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.90m (up NZ$1.58m from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Ankündigung • Aug 15
Rua Bioscience Limited, Annual General Meeting, Oct 28, 2025 Rua Bioscience Limited, Annual General Meeting, Oct 28, 2025. New Risk • May 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.5m free cash flow). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (NZ$1.1m revenue, or US$629k). Market cap is less than US$10m (NZ$6.49m market cap, or US$3.83m). New Risk • Mar 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$3.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.5m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Revenue is less than US$1m (NZ$1.1m revenue, or US$595k). Market cap is less than US$10m (NZ$6.35m market cap, or US$3.55m). New Risk • Feb 06
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 38% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Revenue is less than US$1m (NZ$316k revenue, or US$179k). Market cap is less than US$10m (NZ$6.35m market cap, or US$3.60m). Ankündigung • Jan 21
Rua Bioscience Announces Support for Clinical Study That Harnesses the Potential of Psilocybin-Containing Mushrooms to Treat Methamphetamine Addiction Rua Bioscience announced its support for a clinical study that harnesses the potential of psilocybin-containing mushrooms to treat methamphetamine addiction. This pioneering research, rooted in an indigenous community and guided by mtauranga Mori, has reached a significant milestone. Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessions with mushroom extract containing a specific dose of psilocybin at Rangiwaho Marae, near Gisborne. This marks an important step in Phase I of the trial. Learnings from this first phase will guide the next steps, focusing on the intervention's safety, acceptability, feasibility, and alignment with tikanga and mtauranga Mori. Collaborative Effort Rooted in Tikanga Mori: The study, named T Wairua (standing with strength and spiritual connectedness), represents a collaboration among Rangiwaho Marae, Rua Bioscience, and other research and health organizations. The initiative blends local Mori knowledge with cutting-edge scientific research to explore the therapeutic potential of indigenous Psilocybe fungi (taonga). Tu Wairua is undertaking cultivation trials of taonga varieties with the support from Rua Bioscience and Manaaki Whenua Landcare Research and the Institute of Environmental Science and Research (ESR) is providing analytical support. The psilocybin used in this trial was supplied by Canadian company Optimi Health. Marae-based kaitieki (guides) have been trained in collaboration with kaupapa Mori and psychedelic therapy trainers to provide culturally informed support for participants throughout the trial. Phase I of the study received full approval earlier 2025 from both the Health & Disability Ethics Committees (HDEC) and the Standing Committee on Therapeutic Trials (SCOTT). The research team is currently fundraising for Phase II of the clinical trial, which will expand upon these early findings. Ankündigung • Dec 19
Rua Bioscience Announces Launch of New Products in the UK Rua Bioscience announced the launch of three medicinal cannabis products in the United Kingdom. This marks a significant milestone in Rua's international growth strategy, with the UK positioned as a key market alongside Germany, Australia, and New Zealand. These new products will be distributed exclusively by Target Healthcare, a leading distributor of unlicenced medicines in the UK. Unlocking the Potential of a Growing Market The UK medicinal cannabis market is estimated to be one of the fastest growing in Europe, driven by an increasing number of patients seeking alternative medicines for the treatment of chronic pain, anxiety, and other conditions. The market is approximately $60m and growing at over 100% per annum in the last two years. With a population of 68 million, Rua expects this market to grow significantly in the next two years. Rua's entry into this market is the next stage in the establishment of a consistent supply line and respected presence. New Risk • Nov 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.7m free cash flow). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (NZ$316k revenue, or US$188k). Market cap is less than US$10m (NZ$5.08m market cap, or US$3.02m). Minor Risk Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Ankündigung • Oct 21
Rua Bioscience Limited Provides Sales Results for the Year 2025 Rua Bioscience Limited provided sales results for the year 2025. The company expects to see all markets continue to grow over the medium term as medicinal cannabis gains acceptance and is understood as a legitimate, safe and efficacious treatment option in key markets. Importantly this means sales revenue will continue to grow as the company now firmly established in three key markets with strong revenue growth. In addition, the company is expected to launch Rua product in a fourth key market, United Kingdom, in the next two months. It is for these reasons that The company expects 2025 revenue to show significant growth. New Risk • Oct 20
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.7m free cash flow). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (NZ$316k revenue, or US$192k). Market cap is less than US$10m (NZ$7.86m market cap, or US$4.77m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Reported Earnings • Oct 05
Full year 2024 earnings released: NZ$0.087 loss per share (vs NZ$0.039 loss in FY 2023) Full year 2024 results: NZ$0.087 loss per share (further deteriorated from NZ$0.039 loss in FY 2023). Net loss: NZ$13.7m (loss widened 130% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 30
Full year 2024 earnings released: NZ$0.09 loss per share (vs NZ$0.039 loss in FY 2023) Full year 2024 results: NZ$0.09 loss per share (further deteriorated from NZ$0.039 loss in FY 2023). Net loss: NZ$13.7m (loss widened 130% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Ankündigung • Aug 19
Rua Bioscience Limited, Annual General Meeting, Oct 15, 2024 Rua Bioscience Limited, Annual General Meeting, Oct 15, 2024. New Risk • Feb 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 7.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Share price has been highly volatile over the past 3 months (7.0% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$406k). Market cap is less than US$10m (NZ$15.8m market cap, or US$9.61m). New Risk • Jan 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: NZ$15.8m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$409k). Market cap is less than US$10m (NZ$15.8m market cap, or US$9.67m). Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change). New Risk • Oct 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 7.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$389k). Market cap is less than US$10m (NZ$16.6m market cap, or US$9.67m). Minor Risk Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Ankündigung • Sep 05
Rua Bioscience Launches First Product in Australia Rua Bioscience announced its official entry into the dynamic Australian medicinal cannabis market. Teaming up with Anspec, a leading pharmaceutical distribution company, Rua Bioscience product is now available to Australian patients through prescribers. In 2022, the Australian cannabis market was valued at AUD 240 million per year. Reported Earnings • Aug 30
Full year 2023 earnings released: NZ$0.04 loss per share (vs NZ$0.06 loss in FY 2022) Full year 2023 results: NZ$0.04 loss per share (improved from NZ$0.06 loss in FY 2022). Net loss: NZ$5.96m (loss narrowed 31% from FY 2022). Ankündigung • Aug 18
Rua Bioscience Limited, Annual General Meeting, Oct 11, 2023 Rua Bioscience Limited, Annual General Meeting, Oct 11, 2023, at 10:00 NZST - New Zealand Standard. New Risk • Jul 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of New Zealander stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.9m free cash flow). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (NZ$526k revenue, or US$327k). Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Market cap is less than US$100m (NZ$24.8m market cap, or US$15.5m). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Teresa Farac-Ciprian was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 17
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Teresa Farac-Ciprian was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 21
Rua Bioscience Limited Announces Executive Changes Rua Bioscience Limited announces that Andi Grant is to step down from the role of Chief Commercial Officer. The role will be filled by current Chief Operating Officer, Paul Naske. Andi joined Rua in June 2021 and has substantially progressed Rua's global and New Zealand business goals. Paul Naske has been overseeing Rua's topline business operations since the beginning of 2019 and has been critical in the design and efficient execution of Rua's global strategy. Board Change • Sep 08
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman Trevor Burt was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Aug 26
Rua Bioscience Limited to Report Fiscal Year 2022 Results on Aug 29, 2022 Rua Bioscience Limited announced that they will report fiscal year 2022 results on Aug 29, 2022 Ankündigung • Aug 23
Rua Bioscience Limited, Annual General Meeting, Oct 12, 2022 Rua Bioscience Limited, Annual General Meeting, Oct 12, 2022, at 10:00 NZST - New Zealand Standard. Location: Waikanae Surf Club, Grey St Gisborne New Zealand Ankündigung • Apr 19
Rua Bioscience Limited Launches Its First Medicine in New Zealand Rua Bioscience has launched its first medicine, marking a significant milestone for New Zealand patients, prescribers and the medicinal cannabis industry. Available on prescription in New Zealand, GPs and specialists who are registered medical practitioners will now be able to include Rua medicine in patient treatment plans. Manufactured in the company's purpose-built facility in Gisborne, and distributed nationally via CDC Pharmaceuticals, sales from the product will be the first revenue for the business, which listed on the NZX in 2020. Board Change • Dec 31
High number of new directors Non-Executive Director Brett Gamble was the last director to join the board, commencing their role in 2019. Ankündigung • Dec 17
Rua Bioscience Given the Green Light to Distribute First Product to New Zealand Patients Rua Bioscience has received verification that its first medicinal cannabis product meets the NZ Medicinal Cannabis Agency's (Medsafe's) quality standards, enabling the company to distribute its first medicine in New Zealand. The approval of the product means that New Zealand patients and prescribers can include the Rua product in their treatment plan. The company intends to distribute product by the end of first quarter, early second quarter 2022. It will be made available as a prescription-only medicine through GPs and specialists. The company be will manufacturing the medicine in its purpose-built facility in Gisborne, having gained Good Manufacturing Practice (GMP) certification for the product earlier 2021. Ankündigung • Dec 02
Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million. Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million on November 30, 2021. The consideration at Enterprise value of NZD 8.5 million is net of Zalm Cash. The consideration will be satisfied through issue of 24,420,000 new Rua shares at approximately NZD 0.41 (based on 60-day VWAP) in three tranches, first tranche of shares to the value of NZD 3.3 million in 8,140,000 shares will be issued on completion of the transaction. The remaining consideration will be paid in equal instalments, conditional on Zalm achieving critical production, pricing and regulatory milestones by December 30, 2022 and March 31, 2024 respectively. If neither of the two milestones is achieved, approximately NZD 0.5 million of cash will be released to Cann Group and Rua would have paid NZD 3.3 million for Zalm ( NZD 2.3 million net of cash). Peter Crock, Cann’s Chief Executive Officer and Allan McCallum, AO, Cann’s Chairman, will both step down as directors of Zalm as part of the transaction, while Peter Crock and Shane Duncan (Cann’s Chief Operating Officer), will join the Transition Advisory Board to help maximise and accelerate the potential of this opportunity. The transaction is subject to approval from Rua’s shareholders, which is expected to occur by January 31, 2022. Is New 90 Day High Low • Feb 26
New 90-day low: NZ$0.48 The company is down 15% from its price of NZ$0.57 on 27 November 2020. The New Zealander market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period. Is New 90 Day High Low • Jan 28
New 90-day low: NZ$0.50 The company is down 24% from its price of NZ$0.66 on 30 October 2020. The New Zealander market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period. 